Jiang S - Search Results

1

The development of small-molecule inhibitors targeting HPK1.

Zhou L, Wang T, Zhang K, Zhang X, Jiang S. Zhou L, et al. Among authors: jiang s. Eur J Med Chem. 2022 Dec 15;244:114819. doi: 10.1016/j.ejmech.2022.114819. Epub 2022 Oct 4. Eur J Med Chem. 2022. PMID: 36209628 Review.

2

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.

Zhang K, Chen D, Ma K, Wu X, Hao H, Jiang S. Zhang K, et al. Among authors: jiang s. J Med Chem. 2018 Aug 23;61(16):6983-7003. doi: 10.1021/acs.jmedchem.8b00124. Epub 2018 May 7. J Med Chem. 2018. PMID: 29712428 Review.

3

Cobalt-catalyzed carbon-sulfur/selenium bond formation: synthesis of benzo[b]thio/selenophene-fused imidazo[1,2-a]pyridines.

Wang T, Chen J, Wang J, Xu S, Lin A, Yao H, Jiang S, Xu J. Wang T, et al. Among authors: jiang s. Org Biomol Chem. 2018 May 23;16(20):3721-3725. doi: 10.1039/c8ob00743h. Org Biomol Chem. 2018. PMID: 29737996

4

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.

Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S. Wang T, et al. Among authors: jiang s. J Med Chem. 2019 Feb 28;62(4):1715-1730. doi: 10.1021/acs.jmedchem.8b00990. Epub 2018 Oct 9. J Med Chem. 2019. PMID: 30247903 Review.

5

Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.

Zhang K, Ni Y, Chen J, Tu Z, Wu X, Chen D, Yao H, Jiang S. Zhang K, et al. Among authors: jiang s. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1502-1506. doi: 10.1016/j.bmcl.2019.04.013. Epub 2019 Apr 8. Bioorg Med Chem Lett. 2019. PMID: 30992165

6

Targeting tropomyosin receptor kinase for cancer therapy.

Miao Q, Ma K, Chen D, Wu X, Jiang S. Miao Q, et al. Among authors: jiang s. Eur J Med Chem. 2019 Aug 1;175:129-148. doi: 10.1016/j.ejmech.2019.04.053. Epub 2019 Apr 30. Eur J Med Chem. 2019. PMID: 31077998 Review.

7

Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.

Zhang K, Yao Y, Tu Z, Liao C, Wang Z, Qiu Y, Chen D, Hamilton DJ, Li Z, Jiang S. Zhang K, et al. Among authors: jiang s. Future Med Chem. 2020 Feb;12(4):311-323. doi: 10.4155/fmc-2019-0290. Epub 2019 Nov 29. Future Med Chem. 2020. PMID: 31782319

8

Cyclin-dependent kinase 7 inhibitors in cancer therapy.

Wang M, Wang T, Zhang X, Wu X, Jiang S. Wang M, et al. Among authors: jiang s. Future Med Chem. 2020 May;12(9):813-833. doi: 10.4155/fmc-2019-0334. Epub 2020 Mar 25. Future Med Chem. 2020. PMID: 32208930 Review.

9

Suppression of Musashi‑2 by the small compound largazole exerts inhibitory effects on malignant cells.

Wang M, Sun XY, Zhou YC, Zhang KJ, Lu YZ, Liu J, Huang YC, Wang GZ, Jiang S, Zhou GB. Wang M, et al. Among authors: jiang s. Int J Oncol. 2020 May;56(5):1274-1283. doi: 10.3892/ijo.2020.4993. Epub 2020 Feb 19. Int J Oncol. 2020. PMID: 32319553

10

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.

Zhang W, Zhang K, Yao Y, Liu Y, Ni Y, Liao C, Tu Z, Qiu Y, Wang D, Chen D, Qiang L, Li Z, Jiang S. Zhang W, et al. Among authors: jiang s. Eur J Med Chem. 2021 Feb 5;211:113022. doi: 10.1016/j.ejmech.2020.113022. Epub 2020 Nov 13. Eur J Med Chem. 2021. PMID: 33239261

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16,452 results

Search Page